Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from SKYE

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 150 points on Monday.

Benzinga

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Skye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab.

Benzinga

Could This New Drug Be The Safer Way To Fight Obesity?

On Friday, Skye Bioscience, Inc. (NASDAQ:SKYE) announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

On Thursday, Skye Bioscience Inc. (NASDAQ:SKYE) reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody.

Benzinga

Inside Chris Sharp's Journey to Transform Regenerative Medicine Through Biotechnology

Sharp has led Skye Biologics to treat over 600,000 patients and build one of the industry's most diverse portfolios of naturally derived allograft products.

International Business Times

Why Everyone’s Talking About Penrith and Skye at Holland

In today’s ever-evolving property market, two names keep popping up in conversations—Penrith and Skye at Holland

inkl

Look inside the 2025 Scotland’s Home of the Year finalists

THE six properties competing for the coveted title of Scotland's Home of the Year 2025 have been revealed

The National (Scotland)

Read news from The Economist, FT, and more,
with one subscription

Is This Penny Stock’s 525% Upside Potential an Attainable Goal?

Skye Bioscience is trying to establish a presence in the weight-loss drug market.

Barchart

Makeup-free Pamela Anderson was an ethereal vision in the butter yellow Oscar de la Renta gown of our dreams

Minimalist and absolutely stunning - Pamela Anderson was pared back perfection on the red carpet in Oscar de la Renta, and her no makeup era is her finest yet.

Woman & Home

8 of the best Scotland islands for rugged coastlines and picturesque villages

Sail away from the mainland to explore spectacular scenery and diverse wildlife in these unspoiled spots

The Independent UK

The Callum Skye is a luxury all-terrain EV built for adventure

Skye is the first all-new car developed by former Jaguar and Aston Martin designer Ian Callum

2 Growth Stocks With 20% to 40% Upside in 2024

Both of these companies’ innovative products present excellent long-term opportunities for investors seeking growth in the stock market.

Barchart

Lucy Mary hosts a perfect trip cruising the West Coast

‘I’VE never seen a year on the west coast like it,” beams captain James Fairbairns from the helm of the Lucy Mary, the new small ship opening…

The National (Scotland)

Cow stuck at bottom of cliff rescued by Scots firefighters after battle against incoming tide

SFRS teams from Lochalsh & Wester Ross, Skye & Raasay, and Inverness & Kyle were called after the animal escaped its field and ended up on the rocky shoreline.

Daily Record

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma

Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer that it has completed the production of SBI-100 Ophthalmic Emulsion (&ld

Benzinga

Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer

Skye Bioscience, Inc. (OTCQB: SKYE) , a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing organization (“CMO”) for its Phase 2 clinical trial mat

Benzinga

Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details

Skye Bioscience, Inc. (OTCQB: SKYE) and Emerald Health Therapeutics, Inc.

Manchester Evening News

Smyths Toys Superstores announces Stockport opening date

Cocomelon's JJ and Paw Patrol's Chase and Skye will be appearing as part of the launch celebrations

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Skye Bioscience Shares Up On Keeping Novotech As CRO For Phase 1 Trial Of THC Prodrug Candidate For Glaucoma

Skye Bioscience, Inc. (OTCQB: SKYE) has entered into an agreement with Novotech Health Holdings, a leading full-service contract research organization in Asia-Pacific, for its upcoming Phase 1 study in Australia of its SBI-100 drug candidate for the treatment of glaucoma.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.